Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells

International Journal of Oncology

Volumn 37, Issue 2, 2010, Pages 419-428

  Jeon, Heui Sook ^a   Ahn, Mee Young ^a   Park, Ji Hye ^a   Kim, Tae Hyung ^a   Chun, Pusoon ^a   Kim, Won Hee ^a   Kim, Jungsu ^a   Moon, Hyung Ryong ^a   Jung, Jee H ^a   Kim, Hyung Sik ^a  

^a Pusan National University   (South Korea)

Author keywords

Apoptosis; Hydroxamic acid derived histone deacetylase; MHY218; Ovarian cancer; Suberoylanilide hydroxamic acid

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME C; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; MHY 218; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; VORINOSTAT; ANTINEOPLASTIC AGENT; DIPHENYL ETHER DERIVATIVE; HYDROXAMIC ACID; N1 HYDROXY N8 (4 PHENOXYPHENYL)OCTANEDIAMIDE; N1-HYDROXY-N8-(4-PHENOXYPHENYL)OCTANEDIAMIDE; PIMELIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NICK END LABELING; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; BIOLOGICAL MODEL; CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; OVARY TUMOR; PATHOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; G2 PHASE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; PHENYL ETHERS; PIMELIC ACIDS; TUMOR CELLS, CULTURED;

EID: 77954160845     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000690     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer Statistics. CA Cancer J Clin 58: 71-96, 2008.
2. Naora H and Montell DJ: Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5: 355-366, 2005. (Pubitemid 40637827)
3. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R and Pavletich NP: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193, 1999. (Pubitemid 29436325)
4. Mei S, Ho AD and Mahlknecht U: Role of histone deacetylase inhibitors in the treatment of cancer (Review). Int J Oncol 25: 1509-1519, 2004.
5. Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T, Matsumoto Y and Iwamoto Y: Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 116: 784-792, 2005.
6. Pan LN, Lu J and Huang B: HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immun 4: 337-343, 2007.
7. Wade PA: Transcriptional control at regulatory checkpoint by histone deacetylase: molecular connections between cancer and chromatin. Hum Mol Genet 10: 693-698, 2001.
8. Feinberg AP, Ohlsson R and Henikoff S: The epigenetic progenitor origin of human cancer. Nature Rev 7: 21-33, 2006.
9. Glaser KB: HDAC inhibitors: Clinical update and mechanism based potential. Biochem Pharmacol 74: 659-671, 2007.
10. Kang MR, Kang JS, Han SB, Kim JH, Kim DM, Lee K, Lee CW, Lee KH, Lee CH, Han G, Kang JS, Kim HM and Park SK: A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells. Biochem Pharmacol 78: 486-494, 2009.
11. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM and Frankel SR: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39, 2007.
12. Kuo PH, Carlson KR, Christensen I, Girardi M and Heald PW: FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial. Mol Imaging Biol 10: 306-314, 2008.
13. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA and Richon VM: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170, 2000.
14. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ and Johnstone RW: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98: 10833-10838, 2001.
15. Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356, 2007.
16. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP and Parsons PG: Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80: 1252-1258, 1999.
17. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T and Nakanishi O: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96: 4592-4597, 1999.
18. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I and Coombes RC: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976, 2001.
19. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE and Thiele CJ: MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62: 6108-6115, 2002.
20. Ahn MY, Lee J, Na YJ, Choi WS, Lee BM, Kang KW and Kim HS: Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells. Chem Biol Interact 179: 169-177, 2009.
21. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
22. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Saito M, Kawagoe J, Takahashi K, Yada-Hashimoto N, Sakata M, Motoyama T, Kurachi H, Tasaka K and Murata Y: Inhibition of NFkappaB increases the efficacy of cisplatin in vitro and in vivo ovarian cancer models. J Biol Chem 279: 23477-23485, 2004.
23. Hashimoto K, Morishige K, Sawada K, Tahara M, Kawagishi R, Ikebuchi Y, Sakata M, Tasaka K and Murata Y: Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res 65: 540-545, 2005.
24. Acharya MR, Sparreboom A, Venitz J and Figg WD: Rational development of histone deacetylase inhibitors as anticancer agents: A review. Mol Pharmacol 68: 917-932, 2005.
25. Jung M: Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 8: 1505-1511, 2001. (Pubitemid 32894012)
26. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006. (Pubitemid 44348499)
27. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP and Gottlicher M: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455-463, 2004. (Pubitemid 38610247)
28. WAF1/CIP1 expression, independent of histone deacetylase 1. Cell Death Differ 12: 395-404, 2005.
29. Grozinger CM and Schreiber SL: Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9: 3-16, 2002.
30. de Ruijter AJ, van Gennip AH, Caron HN and Kemp S: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749, 2003.
31. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M and Tsuneyoshi M: Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18: 769-774, 2007.
32. Miller TA, Witter DJ and Belvedere S: Histone deacetylase inhibitors. J Med Chem 46: 5097-5116, 2003.
33. Huang L and Pardee AB: Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6: 849-866, 2000.
34. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 673-678, 2005.
35. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
36. Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW and Koeffler HP: SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 15: 187-191, 2006.
37. Fedier A, Dedes KJ, Imesch P, Von Bueren AO and Fink D: The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol 31: 633-641, 2007.
38. WAF1/CIP1 at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18: 629-643, 1998.
39. Liotta LA: Tumor invasion and metastasis role of the extracellular matrix. Cancer Res 46: 1-7, 1986.
40. Kim JS, Lee S, Lee T, Lee YW and Trepel JB: Transcriptional activation of p21WAF1/CIP1 by apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 281: 866-871, 2001.
41. Pulukuri SM, Gorantla B and Rao JS: Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem 282: 35594-35603, 2007.
42. Kim SH, Ahn S, Han JW, Lee HW, Lee HY, Lee YW, Kim MR, Kim KW, Kim WB and Hong S: Apicidin is a histone deacetylase inhibitor with anti-invasive and anti angiogenic potentials. Biochem Biophys Res Commun 315: 964-970, 2004.
43. Glozak MA and Seto E: Histone deacetylase and cancer. Oncogene 26: 5420-5432, 2007.
44. Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN and Brentani MM: Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 16: 577-585, 1998. (Pubitemid 29044580)
45. Duffy MJ, Maguire TM, Hill A, McDermott E and O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2: 252-257, 2000. (Pubitemid 32223594)
46. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M and Horinouchi S: Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 98: 87-92, 2001.
47. Thangaraju M, Carswell KN, Prasad PD and Ganapathy V: Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J 417: 379-389, 2009.